(0.00%) 5 478.75 points
(-0.01%) 38 815 points
(0.04%) 19 929 points
(0.30%) $80.57
(0.65%) $2.81
(0.15%) $2 332.60
(-0.24%) $29.32
(-0.02%) $970.70
(0.03%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies...
Stats | |
---|---|
Šios dienos apimtis | 1 345 |
Vidutinė apimtis | 867 971 |
Rinkos kapitalizacija | 406.40M |
EPS | $-0.0952 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.0800 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.13 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00400 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-31 | Shah Rutul R | Buy | 550 000 | Option to Purchase Common Stock (Right to Buy) |
2024-05-31 | Perez Jeffrey Thomas | Buy | 300 000 | Option to Purchase Common Stock (Right to Buy) |
2024-05-31 | Sabzevari Helen | Buy | 1 803 000 | Option to Purchase Common Stock (Right to Buy) |
2024-05-31 | Thomasian Harry Jr. | Buy | 500 000 | Option to Purchase Common Stock (Right to Buy) |
2024-05-31 | Lehr Donald P. | Buy | 400 000 | Option to Purchase Common Stock (Right to Buy) |
INSIDER POWER |
---|
71.95 |
Last 100 transactions |
Buy: 25 508 369 | Sell: 4 433 991 |
Tūris Koreliacija
Precigen Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Precigen Inc Koreliacija - Valiuta/Žaliavos
Precigen Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $6.23M |
Bruto pelnas: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2023 |
Pajamos: | $6.23M |
Bruto pelnas: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2022 |
Pajamos: | $26.91M |
Bruto pelnas: | $20.57M (76.44 %) |
EPS: | $-0.400 |
FY | 2021 |
Pajamos: | $103.87M |
Bruto pelnas: | $45.49M (43.79 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Precigen Inc
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.